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Abstract  
Rationale: Neutrophils are upregulated in infectious processes. They can be measured as 
surrogates for the presence of an infection. Flow cytometry is a common tool that uses 
fluorochrome-conjugated antibodies specific to cell-surface biomarkers to identify cells or 
biomarkers of interest. Many clinical flow cytometry protocols exist that assess lymphocytes, but 
fewer protocols exist for rapid clinical evaluation of neutrophils. Expression of neutrophil cell-
surface markers integrin α9β1 and CD11b has been shown to increase in elderly patients with 
bacterial pneumonia. A rapid clinical test for these neutrophil cell-surface markers could help to 
expedite appropriate antibiotic therapy to patients suffering from complex critical illnesses 
complicated by bacterial pneumonia for which other diagnostic methods are rendered inadequate. 
Methods: We developed a rapid lyse, no-wash clinical protocol for flow cytometric 
analysis of neutrophil cell-surface biomarkers integrin α9β1 and CD11b from whole blood 
samples. Assay development included selecting appropriate neutrophil-specific biomarkers and 
their corresponding fluorochrome profile, determining the most consistent blood acquisition 
method (BAM) for obtaining samples for analysis, and evaluating the effect of preservative type 
and time on neutrophil absolute count (ANC), integrin α9β1 mean fluorescence intensity (MFI), 
and CD11b MFI. 
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Results: There were significant differences in ANC, CD11b MFI, and integrin α9β1 MFI 
over time for each BAM and Preservative type. ANC demonstrated the least variability in Citrate, 
while CD11b MFI and integrin α9β1 MFI were most consistent in Heparin. Therefore, Heparin 
was selected as the BAM of choice. Streck preservative solution and Streck Blood Collection Tube 
(BCT) demonstrated the least variability in ANC, integrin α9β1 MFI, and CD11b MFI. 
Conclusions: Pneumonia is difficult to detect in patients with critical illness, where the 
usual diagnostic tools are rendered inadequate secondary to multi-system organ failure. More 
accurate methods of diagnosis for pneumonia can enhance targeted antibiotic therapy and are of 
paramount public health importance to improve patient care. Development of a rapid clinical flow 
cytometric protocol is the first step toward precision methods of pneumonia diagnosis; therefore, 
a rapid lyse/no-wash clinical flow cytometric assay for whole blood specimens was developed for 
identification of neutrophil cell-surface biomarkers CD11b and integrin α9β1. Heparin was the 
least variable BAM for assessing CD11b MFI and integrin α9β1 MFI, while Streck preservative 
solution and Streck BCT demonstrated the least variability over 24 hours from specimen 
collection. Heparin is a common type of venipuncture tube in hospitals, it is not as cost effective 
or feasible to purchase a separate blood collection tube (e.g. Streck BCT) for a single laboratory 
test. Given these real-world concerns, Streck solution added to samples collected in heparin 
venipuncture tubes is the most reasonable method by which to perform the rapid lyse/no-wash 
neutrophil flow cytometric assay. 
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1.0 Introduction 
Bacterial pneumonia is a common infection resulting in over 544,000 annual Emergency 
Department visits and killing 48,632 people annually in the United States1,2. Certain patient 
populations have a higher risk of developing pneumonia, such as elderly people who are at risk for 
aspiration following a stroke or other disease process resulting in impaired swallowing or an 
impaired gag reflex3. Oftentimes, the diagnosis of pneumonia is not straightforward due to 
confounding complex medical illness and non-infectious inflammation that obscures radiographic 
findings. This is especially true in patients resuscitated from cardiac arrest and is related to the 
sepsis-like inflammatory cascade they develop following ischemia and reperfusion from the arrest 
and subsequent resuscitation. Therefore, more sensitive and specific biomarkers are needed to 
diagnose pneumonia in multiple patient populations. A prior study in elderly patients with 
aspiration pneumonia demonstrated differential expression of neutrophil cell-surface markers 
integrin α9β1 and CD11b, as assessed by flow cytometry, in patients with pneumonia as compared 
to those without3. Presence of differential expression of these neutrophil biomarkers in complex 
critical illness states (e.g. patients after resuscitation from cardiac arrest) could specify the 
diagnosis of pneumonia, allowing clinicians to more rapidly identify the disease and effectively 
allocate antibiotic therapy. 
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1.1 Neutrophil Cell-Surface Biomarkers and the Immunology of Pulmonary 
Infection 
Neutrophils are known to be upregulated in infectious processes, and specific neutrophil 
cell-surface biomarkers could serve as a target for further study as surrogates of pulmonary 
infection. The biomarkers of interest in this study were chosen based on their physiologic relation 
to the development of infectious pulmonary inflammation in pneumonia3-8. Neutrophils are 
upregulated via the TH17 pathway, through activation by Interleukin 17A (IL-17A), in pulmonary 
infections3,11,12.  TH17 cells are a subset of CD4+ T cells that play a key role in mucosal immunity, 
hence their importance in pulmonary infections and the innate immune response11,12. Alveolar 
macrophages secrete IL-23, which activates TH17 cells to produce IL-17A, which is essential for 
neutrophil migration in pulmonary infection, particularly to lipopolysaccharides, which are 
lipoglycans and endotoxins released by bacteria3,11-16.  
Integrins facilitate the human inflammatory response by mediating neutrophil adhesion and 
extravasation to the site of infection4,9. Integrins are transmembrane glycoproteins composed of 
two subunits, α and β, that form a heterodimer which spans the cell membrane9. The β subunit 
generally enables cell attachment while the α9 subunit is more specific and known to be crucial to 
the pulmonary innate immune system response9,10. Research at the molecular level has 
demonstrated that integrin α9β1 is expressed on neutrophils and that vascular cell adhesion 
molecule-1 (VCAM-1) acts as a ligand for integrin α9β1, facilitating neutrophil transmigration 
during infectious and inflammatory states4,10. CD11b is a β2 integrin expressed in complex with 
CD18 on the surface of leukocytes including neutrophils, monocytes, and NK cells5. CD11b is 
upregulated as part of the innate immune response to infections and induces cell adhesion, it also 
acts as a complement receptor5,6,7. Prior studies have demonstrated upregulation of CD11b in 
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community acquired pneumonia, where it facilitates migration of neutrophils to the site of 
pulmonary infection3,5.  
1.2 Neutrophil Flow Cytometric Assays  
Flow cytometry is a common technique to assess cell populations and cell-surface 
biomarker expression. Prior study in elderly patients with aspiration pneumonia demonstrated 
differential expression of neutrophil cell-surface markers integrin α9β1 and CD11b, as assessed 
by flow cytometry, in patients with pneumonia as compared to those without3. However, this study 
did not analyze specimens in real-time; rather, patient samples were stored and frozen at -80°C, 
which could affect the integrity of neutrophils and the expression of integrin α9β1 and CD11b. 
There is evidence in the literature that increasing the temperature from 4°C to 37°C can upregulate 
CD11b expression while hypothermia can inhibit expression, so it is recommended that samples 
either be kept on ice for procedures or maintained at room temperature17,18,22. Prior studies also 
suggest that cell damage can result in non-specific binding of antibodies to cell membranes, which 
can alter the fluorescence profiles for both cells and their membrane biomarkers17,20. 
The literature concerning how citrate, heparin, and EDTA anticoagulants influence CD11b 
expression is conflicting. Heparin was found to significantly elevate cytokines as compared to 
citrate or EDTA; however, these assays used plasma, whereas this study is analyzing biomarkers 
from whole blood19. Henno et al. determined that serum collected in EDTA, heparin, and citrate 
resulted in higher cytokine levels than plasma, while storage of whole blood at room temperature 
resulted in elevated levels of some cytokines due to in vitro release from cells20,23. Henno et al. 
and Patil et al. noted varied expression among different cytokines depending on the anticoagulant 
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used, but none of the cytokines in these studies overlap with those being evaluated in this study20,23. 
EDTA demonstrated superior elevation of neutrophils as compared to heparin or citrate for direct 
isolation from whole blood, but a density gradient with centrifugation was used for neutrophil 
isolation, which is a different approach than employed in this study21. No studies were identified 
that directly matched the protocols described herein; therefore, guidance from the literature is 
limited in its relationship to this study. 
The goal of developing this assay was to create a clinical test to rapidly evaluate the 
differential expression of neutrophil cell-surface biomarkers for diagnosis of pulmonary infection. 
Freezing or otherwise manipulating neutrophils may not only alter the biomarkers of interest, as 
described previously, it also results in delay of testing and dissemination of results to clinicians. 
Given the lack of consensus regarding the appropriate anticoagulant venipuncture specimen 
collection tube as well as the most ideal cell preservative, further study is warranted to determine 
the optimal specimen collection and preservative conditions for neutrophils and their cell-surface 
biomarkers. In order to develop a rapid lyse/no-wash protocol to assess neutrophil-specific cell-
surface expression of integrin α9β1 and CD11b, we evaluated the variability over time of 
biomarker expression between three different blood acquisition methods and three different 
preservative types. 
 5 
2.0 Methods 
2.1 Blood Donors 
Verbal consent for peripheral venipuncture was obtained from 16 healthy donors associated 
with this project who had no known inflammatory or rheumatologic diseases, cancer, or 
immunosuppression. A total of six subjects provided specimens for the blood acquisition method 
experiment and 10 subjects provided blood for the preservative experiment. This project was 
considered by the Institutional Review Board to be a quality improvement analysis for calibration 
of a laboratory technique.  
2.2 Blood acquisition and preparation  
For analysis of the blood acquisition method (BAM), samples were collected in BD 
Vacutainer sodium citrate, BD Vacutainer heparin sulfate, and BD Vacutainer K2 
ethylenediaminetetraacetic acid (ETDA) venipuncture tubes. For analysis of preservative types, 
samples were collected in BD Vacutainer heparin sulfate tubes and Streck Blood Collection Tubes 
(BCT).  
Whole blood collected for the blood acquisition method (BAM) assays was divided evenly 
and Streck preservative solution was added to half of the samples in a 1:1 ratio for each BAM 
tested. Whole blood for the preservative assays was either left unadulterated (control), had Streck 
preservative solution added in a 1:1 ratio, or was collected in a Streck BCT direct-draw blood 
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collection tube. 4′,6-Diamidino-2-phenylindole dihydrochloride (DAPI, 10 µL of 200 µg/mL 
solution) stain was added to the control samples in the preservative comparison experiments just 
prior to flow cytometry analysis to discriminate between intact, live cells and dead cells. 
Each assay was performed in triplicate with a fluorescence-minus-one control (FMO)25. 
Samples were processed immediately and at 24 hours post-collection for the BAM analyses as 
well as for the preservative analyses. All samples remained at ambient temperature following 
collection and during analysis. Samples were placed on a nutating mixer between time point 
assays.  
2.3 Flow cytometer calibration 
In a properly calibrated flow cytometer, mean fluorescence intensity (MFI) is a surrogate 
for the relative number of target molecules per cell and can be used to assess changes in biomarker 
expression over time intensity. The cytometer was calibrated before each use with Spherotech 8-
peak Rainbow Particles in order to ensure quantitative comparability of MFI within and between 
experiments. Photomultiplying tubes (PMTs) are sensors in flow cytometers that detect specific 
wavelengths of light filtered within the cytometer. PMT voltages require calibration to ensure 
consistency of measurements; therefore, PMT voltages for all parameters were adjusted to place 
the seventh bead peak (derived from the Spherotech 8-peak Rainbow Particles) in a predetermined 
target channel prior to each experiment. Single stained controls, which are hard-stained beads for 
the dyes used in a flow cytometry experiment (e.g. FITC, PE, APC, antibody capture beads for 
tandem dyes), were run with each experiment for spectral compensation.  
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2.4 Measurement of cell surface chemokine receptors for blood acquisition method 
analyses 
Whole blood (100µL), regardless of BAM type, was incubated at room temperature for 20 
minutes in the dark with CD45 (5 µL, Biolegend #304017, A488, mouse IgG1 k, anti-human, 100 
tests), CD16 (20µL, BD Biosciences #555408, PE-Cy5, mouse IgG1 k, anti-human, 100 tests), 
CD14 (5µL, Biolegend #325618, PE-Cy7, mouse IgG1 k, anti-human, 100 tests), CD33 (10µL, 
Miltenyi Biotec #130-111-022, APC-vio770, human, 100 tests), integrin α9β1 (5µL, Biolegend 
#351606, PE, mouse IgG1 k, anti-human, 100 tests), and CD11b/MAC-1 (20µL, BD Biosciences 
#550019, APC, mouse IgG1 k, anti-human, 100 tests).  PBS (25 µL) was added to the FMO 
samples in order to equalize the volume. Lysing solution (2 mL, IOTest 3, Beckman Coulter 
#A07799) was added to each sample and incubated for 10 minutes in the dark at room temperature. 
Flow-count fluorospheres (100 µL, Beckman Coulter #7547053, 20mL) was added and samples 
were transferred to the flow cytometer (Gallios, 4 laser, Beckman Coulter).  
2.5 Measurement of cell surface chemokine receptors for preservative analyses 
Whole blood, regardless of BAM type, was incubated with CD45 (5 µL, Biolegend 
#304017, A488, mouse IgG1 k, anti-human, 100 tests), CD16 (5 µL, BD Biosciences #557758, 
APC-Cy7, mouse IgG1 k, anti-human, 100 tests), CD66b (5 µL, Invitrogen #25066642, Pe-Cy7, 
mouse IgM k, anti0human, 100 tests), integrin α9β1 (5µL, Biolegend #351606, PE, mouse IgG1 
k, anti-human, 100 tests), and CD11b/MAC-1 (20µL, BD Biosciences #550019, APC, mouse IgG1 
k, anti-human, 100 tests). PBS (25 µL) was added to the FMO samples in order to equalize the 
volume. Lysing solution (2 mL, IOTest 3, Beckman Coulter #A07799) was added to each sample 
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and incubated for 10 minutes in the dark at room temperature. Flow-count fluorospheres (100 µL, 
Beckman Coulter #7547053, 20mL) beads were added and samples were transferred to the flow 
cytometer (Gallios, 4 laser, Beckman Coulter). 
Flow cytometry data was generated and saved in flow cytometry standard (FCS) format 
using Beckman Coulter Kaluza Acquisition for Gallios software. Gating was performed using 
Applied Cytometry VenturiOne® Analysis Software. Two parameter dot plots in log scale were 
used to identify populations of interest. Cells were differentiated from beads using forward-scatter 
intensity versus forward-scatter time-of-flight, after which cells were assessed using a forward-
scatter versus side-scatter intensity plot to eliminate the lysed red blood cells. Next, a CD45 versus 
side-scatter intensity plot identified distinct cell populations of neutrophils, monocytes, 
lymphocytes, and eosinophils. In order to restrict outcomes analysis to neutrophils, all subsequent 
outcomes gating was defined using the neutrophil gate determined in the CD45 versus side-scatter 
intensity plot. Plots of the biomarker of interest versus side-scatter intensity were generated and 
polygonal gates were drawn around populations expressing the target molecule of interest. MFI 
was used to quantify the two primary biomarker outcomes of interest, integrin α9β1 and CD11b. 
Absolute neutrophil count (ANC) was determined using a manufacturer-specified concentration 
of Beckman Coulter Stem Count beads that was added in equal volume (100 µL) to the sample.  
2.6 Selection of Cluster of Differentiation Molecules for Neutrophil Identification 
Neutrophils can be identified by their side scatter and forward scatter properties in flow 
cytometry, in combination with cell-specific cluster of differentiation (CD) molecules. Positive 
selection, in which a cell is classified on the basis of expressing certain molecules, can be combined 
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with negative selection, in which a cell is categorized based on the lack of certain molecules, to 
identify cell types. The CD markers selected for neutrophil identification were CD45, CD16, 
CD14, and CD33 in the BAM analyses. In order to simplify the gating scheme, the CD markers 
were streamlined in the Preservative analyses to include CD45, CD16, and CD66b. CD45 is 
expressed on all hematopoetic cells, CD16 is expressed on neutrophils as well as macrophages and 
NK cells, CD14 is expressed on myelomonocytic cells, CD33 is expressed on monocytes, and 
CD66b is expressed on neutrophils and NK cells24. CD45 was used to categorize neutrophils in 
combination with their side scatter and forward scatter characteristics. Side scatter assesses the 
granularity (or internal complexity) of cells, while forward scatter separates cells based on size. 
Neutrophils are highly granular and display higher intensity side scatter than monocytes or 
lymphocytes. Neutrophils are similar in size but often slightly smaller than monocytes, but they 
are larger than lymphocytes; therefore, neutrophils have a higher intensity forward scatter than 
lymphocytes but are similar to monocytes. Hence, further discrimination between neutrophils and 
monocytes using CD markers demonstrates that neutrophils are CD66b+, CD16+, CD33low, 
CD14low while monocytes are CD45+CD33+CD14+CD16-CD66b-. 
2.7 Statistical Analysis 
Raw data was assessed for normality, using the Shapiro-Wilks test in conjunction with 
histogram, qnorm, and pnorm plots. Comparisons between groups were tested at baseline using 
the Repeated Measures Analysis of Variance (RM-ANOVA) test (IBM Corp. Released 2017. IBM 
SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp.) The Bonferroni correction 
was used to adjust for multiple comparisons. Paired data across time points was tested using the 
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Student’s paired t-test or Wilcoxon signed-rank test, depending on normality (Stata 15SE, 
StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC). 
Sample size calculations were performed in G*Power (G*Power Version 3.1.9.2) and determined 
that a minimum of 6 subjects was required in the RM-ANOVA model with three groups and four 
measurements, assuming 80% power to detect an effect size of 2 with alpha 0.05 and a two-sided 
test. This sample size was also determined to be appropriate for the Wilcoxon signed-rank test and 
the Student’s paired t-test. Six subjects provided specimens for the blood acquisition method 
experiment and 10 subjects provided specimens for the preservative experiment. 
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3.0 Results 
The primary outcomes for both the blood acquisition methods (BAM) and Preservative 
experiments were CD11b Mean Fluorescence Intensity (MFI), Integrin α9β1 MFI, and Absolute 
Neutrophil Count (ANC). The 95% confidence intervals displayed in all figures depicting repeated 
measures ANOVA analyses represent 95% confidence intervals for the estimated marginal means 
of the model, not 95% confidence intervals for the sample means. 
3.1 Normality Testing 
Normality testing for the BAM studies demonstrated that ANC did not require 
transformation to achieve normality in any BAM type, time point, or preservative. The logarithm 
base 10 (log) transformation was necessary for CD11b MFI in Citrate at each time point and for 
both the No Preservative and Streck preservative assays. Integrin α9β1 MFI required log10 
transformation for samples collected in Citrate and assayed at Time 24 hours. CD11b MFI also 
required the log transformation when collected in EDTA or Heparin in Streck preservative at Time 
0 hours. For ease of interpretation, CD11b MFI and Integrin α9β1 MFI were log transformed for 
all the BAM experiments, which maintained normality even when the transformation was not 
initially necessary. Normality testing for the preservative experiments demonstrated that log 
transformation was required for ANC with each preservative type, Integrin α9β1 MFI in Streck 
preservative, and CD11b MFI at each preservative type. Therefore, for ease of interpretation the 
log transformation was applied to ANC, Integrin α9β1 MFI, and CD11b MFI for each preservative 
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type. This did not affect the normality of variables for which no transformation was initially 
necessary. 
3.2 Repeated Measures Analysis of Variance (RM-ANOVA) Assessing Blood 
Acquisition Method 
3.2.1  RM-ANOVA Assessing BAM, Preservative, and Time Effects on 
ANC 
The overall RM-ANOVA model of ANC adjusted for BAM, Preservative type, and Time 
demonstrated a significant difference (p<0.0001) in ANC related to all variables and interaction 
terms tested in the model. The interaction between BAM*preservative*time (Figure 1) was also 
significant (p<0.002). Large effect sizes noted for each term in the model (partial-η2 = 0.554 – 
0.963).  
The RM-ANOVA model of ANC with No Preservative (Figure 2), adjusted for BAM and 
Time, demonstrated a significant (p <0.0001) difference between BAM types and there was also a 
significant interaction between BAM and time (p<0.004). There was no significant difference 
between time points (p = 0.759). Large effect sizes were noted for each significant variable in the 
model (partial-η2 = 0.953 and 0.629, respectively), and there was a small effect size for Time 
(partial-η2 = 0.012). The RM-ANOVA model of ANC with Streck preservative (Figure 3), 
adjusted for BAM and Time, demonstrated a significant difference in ANC between BAM types 
(p<0.0001) and Time points (p<0.0001), and the interaction between BAM and Time was 
significant (p<0.0001). Large effect sizes were noted for each term in the model (partial-η2 = 0.740 
– 0.912).  
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Variability in ANC, adjusted for Time and Preservative type, was assessed for each specific 
BAM. There was no significant difference in ANC related to Time (p = 0.072) or the interaction 
between Preservative and Time (p = 0.538) for Citrate (Figure 4). Preservative had a significant 
effect on ANC in the model (p = 0.044). The effect size was large for Time (partial-η2 = 0.349), 
small for the interaction term (partial-η2 = 0.049), and large for Preservative (partial-η2 = 0.416). 
There was a significant difference (p<0.0001) in ANC between Preservative types and Time points 
for both the Heparin (Figure 5) and EDTA models (Figure 6). Large effect sizes were noted for 
all main effect variables and the interaction term in the Heparin model (partial-η2 = 0.854 – 0.959) 
as well as in the EDTA model (partial-η2 = 0.909 – 0.969).  
Variability of ANC, adjusted for BAM and Preservative type, was assessed for each 
individual Time point. At Time 0 Hours (Figure 7), there was a significant difference in ANC 
between the three BAM (p<0.0001), both Preservative types (p<0.001), and the interaction 
between BAM and Preservative was also significant (p<0.001). There was a large effect size for 
each of these variables (partial-η2 = 0.767 – 0.968). Similarly, at Time 24 hours (Figure 8) there 
was a significant difference in ANC between BAM (p<0.008), Preservative type (p<0.0001), and 
the interaction between BAM and Preservative was also significant (p<0.0001). There was a large 
effect size for each of these variables (partial-η2 = 0.750 – 0.983). 
Further analysis of the change in raw ANC over time demonstrated that ANC declined an 
average of 7.31 – 12.86% over time in Citrate, with Streck preservative mitigating this effect 
(Appendix A, Table 1). Heparin demonstrated an average ANC increase of 16.34 – 52.39% over 
time, which was not mitigated by Streck preservative. EDTA had the greatest increase in ANC 
over time of 22.29 – 122.64%, made more pronounced with Streck preservative. The coefficient 
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of variation for ANC was overall most favorable in Heparin with Streck preservative, Citrate with 
No Preservative, and EDTA with No Preservative (Appendix A, Table 2).  
3.2.2  RM-ANOVA Assessing BAM, Preservative, and Time Effects on 
CD11b MFI 
The overall RM-ANOVA model (Figure 9) for log CD11b MFI was adjusted for BAM, 
time points, and preservative types. The model demonstrated a significant difference in log CD11b 
MFI for BAM (p<0.0001), preservative (p<0.0001), and the interaction terms BAM*preservative 
(p<0.0001), BAM*time (p<0.0001), time*preservative (p<0.0001), and BAM*time*preservative 
(p<0.004). Time had no significant effect on log CD11b MFI in the model (p = 0.373). Large effect 
sizes were noted for each variable and interaction term in the overall RM-ANOVA model for 
CD11b MFI (partial-η2 = 0.100 – 0.919). 
The RM-ANOVA model with No Preservative (Figure 10), adjusted for BAM and Time, 
demonstrated a significant (p <0.001) difference in log CD11b MFI due to Time, BAM (p <0.001), 
and the BAM*time interaction term was also significant in the model (p= 0.002). Large effect sizes 
were noted for each variable (partial-η2 = 0.546 – 0.751). The RM-ANOVA model with Streck 
preservative (Figure 11), adjusted for BAM and Time, demonstrated that BAM (p <0.0001), Time 
(p < 0.0001), and the interaction of BAM and Time (p <0.0001) all significantly impacted log 
CD11b MFI. Large effect sizes were appreciated for each variable in the model (partial-η2 = 0.765 
– 0.982). 
Variability of log CD11b MFI, adjusted for Time and Preservative type (Figure 12), was 
assessed in Citrate. The main effects of Preservative and Time, as well as the interaction between 
Preservative and Time, imparted significant (p<0.0001) differences in log CD11b MFI in Citrate. 
The variables and interaction term each demonstrated large effect sizes (partial-η2 = 0.871 – 
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0.968). Change in log CD11b MFI in Heparin, adjusted for Time and Preservative type (Figure 
13), demonstrated a significant effect of Time (p = 0.014), Preservative (p <0.0001), and the 
interaction between Time and Preservative (p = 0.003) on log CD11b MFI. Large effect sizes were 
found for each variable and interaction term (partial-η2 = 0.549 – 0.932). The change in log CD11b 
MFI in EDTA, adjusted for BAM and Preservative type (Figure 14), demonstrated a significant 
effect of Preservative (p <0.0001) and the interaction between Time and Preservative (p <0.0001) 
on log CD11b MFI. Time did not significantly impact log CD11b MFI in the EDTA model (p = 
0.181). There was a large effect size for each variable and the interaction term (partial-η2 = 0.212 
– 0.934).  
The variability of log CD11b MFI, adjusted for BAM and preservative type, was assessed 
for each individual time point. In the Time 0 hours model (Figure 15), BAM and Preservative 
demonstrated significant main effects (p<0.0001) on log CD11b MFI, while the interaction 
between the two variables was not significant (p = 0.063). There were large effect sizes for each 
variable and the interaction term (partial-η2 = 0.293 – 0.953). Both BAM (p = 0.023) and 
Preservative (p <0.0001) demonstrated significant main effects on log CD11b MFI, and the 
interaction between BAM and Preservative (p <0.0001) was also significant in the Time 24 hours 
model (Figure 16). Large effect sizes were shown for each variable and the interaction term 
(partial-η2 = 0.376 – 0.953). 
Further analysis of the change in the non-transformed value of CD11b MFI over time 
demonstrated that CD11b MFI in Citrate increased by 3.71% over 24 hours with No Preservative 
and decreased 33.38% with Streck preservative (Appendix B, Table 1). CD11b MFI in Heparin 
increased 78.93% over time with No Preservative, whereas CD11b MFI decreased 12.12% over 
time with Streck preservative. CD11b MFI in EDTA showed the greatest increase over time, 
 16 
112.40%, with No Preservative. Adding Streck preservative resulted in a 34.98% decrease in 
CD11b MFI in EDTA over time. The coefficient of variation for CD11b MFI was smallest for 
Heparin with Streck Preservative and Citrate with Streck Preservative (Appendix B, Table 2).  
3.2.3  RM-ANOVA Assessing BAM, Preservative, and Time Effects on 
Integrin α9β1 MFI 
The overall RM-ANOVA model of log Integrin α9β1 MFI (Figure 17), adjusted for the 
main effects of BAM, Preservative type, and Time, demonstrated a significant difference in log 
Integrin α9β1 MFI related to the main effects of BAM and Preservative (p <0.0001). Time was not 
a significant main effect in the model (p = 0.285). The interactions between BAM and Time (p 
<0.0001), BAM and Preservative (p <0.0001), and Time and Preservative (p = 0.025) were also 
significant. The interaction between BAM, Time, and Preservative was not significant (p = 0.193). 
Large effect sizes noted for each variable and interaction term in the model (partial-η2 = 0.141 – 
0.970).  
The RM-ANOVA model of log Integrin α9β1 MFI with No Preservative (Figure 18), 
adjusted for BAM and Time, demonstrated a significant (p <0.0001) difference between BAM 
types, a significant effect of Time (p = 0.021), and there was also a significant interaction between 
BAM and Time (p <0.001). Large effect sizes were noted for each main effect variable as well as 
for the interaction term in the model (partial-η2 = 0.507 – 0.805). The RM-ANOVA model of log 
Integrin α9β1 MFI with Streck preservative (Figure 19), adjusted for BAM and Time, 
demonstrated a significant (p <0.0001) difference in log Integrin α9β1 MFI between BAM types, 
and the interaction between BAM and Time was significant (p <0.011). Time did not show a 
significant effect on log Integrin α9β1 MFI in the model (p = 0.104). Large effect sizes were noted 
for each term in the model (partial-η2 = 0.296 – 0.851). 
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The variability in log Integrin α9β1 MFI, adjusted for Time and Preservative type, was 
assessed for each specific BAM. For the model of log Integrin α9β1 MFI in Citrate (Figure 20), 
there was a significant difference in log Integrin α9β1 MFI related to Time (p = 0.009) and 
Preservative (p <0.0001), but the interaction between Preservative and Time was not significant 
(p = 0.433). The effect size was large for Time (partial-η2 = 0.598) and Preservative (partial-η2 = 
916), but small for the interaction term (partial-η2 = 0.079). There was a significant difference (p 
<0.0001) in log Integrin α9β1 MFI between Preservative types and Time points for the Heparin 
model (Figure 21), and the interaction between Time and Preservative was also significant in this 
model (p = 0.001). Large effect sizes were noted for all main effects and the interaction term 
(partial-η2 = 0.757 – 0.945). The EDTA model, adjusted for Preservative and Time (Figure 22), 
revealed significant differences in log Integrin α9β1 MFI related to the main effects of Time (p = 
0.015) and Preservative (p <0.0001). The interaction between Time and Preservative was not 
significant in the model (p = 0.145). The effect sizes for each main effect variable and the 
interaction term were large (partial-η2 = 0.246 – 0.949). 
Variability of log Integrin α9β1 MFI, adjusted for BAM and Preservative type, was 
subsequently assessed for each individual Time point. At Time 0 hours (Figure 23), there was a 
significant difference in log Integrin α9β1 MFI related to the main effects of BAM (p<0.0001) and 
Preservative type (p<0.0001), and the interaction between BAM and Preservative was also 
significant (p<0.018). There was a large effect size for each of the variables and the interaction 
term (partial-η2 = 0.482 – 0.859). Similarly, at Time 24 hours (Figure 24) there was a significant 
difference in log Integrin α9β1 MFI related to BAM (p<0.001) and Preservative type (p<0.0001), 
and the interaction between BAM and Preservative was also significant (p<0.0001). There was a 
large effect size for each of these variables (partial-η2 = 0.731 – 0.960). 
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Further analysis of the change in the raw Integrin α9β1 MFI over time demonstrated that 
in Citrate, Integrin α9β1 MFI increased an average of 8.56% over time with No Preservative. When 
Streck was added, Integrin α9β1 MFI in Citrate increased only 3.75% over time (Appendix C, 
Table 1). Integrin α9β1 MFI in Heparin decreased by an average of 2.22% over time with No 
Preservative. Integrin α9β1 MFI in Heparin with Streck Preservative resulted in an average 
decrease of 24.62% over time. Integrin α9β1 MFI in EDTA with No Preservative increased by 
33.86% over time, Streck mitigated this effect with an average increase of Integrin α9β1 MFI of 
0.17% over time. The coefficient of variation for Integrin α9β1 MFI was lowest for Citrate with 
Streck, Heparin with either preservative type, and EDTA with No Preservative (Appendix C, 
Table 2).  
3.3 Student’s Paired T-Test and Wilcoxon Signed-Rank Test Analysis of Main 
Effects from Blood Acquisition Method RM-ANOVA Models 
The overall and reduced RM-ANOVA models above demonstrated that significant 
differences existed due to both main effects and interaction terms within the models. Specific 
pairwise comparisons to evaluate each main effect were completed using either the Student’s 
Paired T-Test or the Wilcoxon Signed-Rank Test, depending on normality. 
3.3.1  Student’s Paired T-Test Comparison of each Main Effect on ANC 
The two-sided Student’s paired t-test was used to individually assess the main effects of 
BAM on ANC, controlling for Time and Preservative. There were non-significant differences in 
ANC between Citrate and Heparin at Time 0 with Streck preservative and between Heparin and 
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EDTA at Time 24 hours with Streck preservative. All other pairwise comparisons were significant 
(Table 1).  
Next, the two-sided Student’s paired t-test was used to assess the effect of each Time point 
on ANC, controlling for BAM and Preservative. There were non-significant differences in ANC 
between Time 0 hours and Time 24 hours in Citrate with Streck and Heparin with No Preservative. 
All other differences in ANC between Time points were significant (Table 2).  
A two-sided Student’s paired t-test was also used to assess the effect of each Preservative 
type on ANC, controlling for BAM and Time. There were non-significant differences in ANC 
between Preservative types with Citrate at Time 24 hours and with EDTA at Time 0 hours. All 
other differences in ANC between Preservative types were significant (Table 3). 
3.3.2  Wilcoxon Signed-Rank Test Analysis of each Main Effect on Log 
CD11b MFI 
A two-sided Wilcoxon Signed-Rank test was used to individually evaluate the RM-
ANOVA model main effects (BAM, Time, Preservative) on log CD11b MFI since the non-
transformed variable was not normal and log transformation did not achieve normality across all 
parameters. There were non-significant differences in log CD11b MFI between Citrate and 
Heparin at Time 24 hours with No Preservative and between Citrate and EDTA at Time 24 hours 
with No Preservative. Additionally, there was a non-significant difference in log CD11b MFI 
between Heparin and EDTA at Time 0 hours with Streck preservative. All other differences in log 
CD11b MFI between BAM types were significant, controlling for Time and Preservative variables 
(Table 4).  
The two-sided Wilcoxon Signed-Rank test was then used to determine the effect of Time 
on log CD11b MFI, controlling for BAM and Preservative. There was a non-significant difference 
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in log CD11b MFI between time points at Citrate with No Preservative. All other comparisons 
between Time points were significant for changes in log CD11b MFI (Table 5).  
The two-sided Wilcoxon Signed-Rank test was also used to determine the effect of 
Preservative on log CD11b MFI, controlling for BAM and Time. There were non-significant 
differences in log CD11b MFI between Preservative types at Time 0 hours in Citrate and at Time 
0 hours in Heparin. All other differences in log CD11b MFI between Preservative types were 
significant (Table 6). 
3.3.3  Student’s Paired T-Test Analysis of Each Main Effect on Log 
Integrin α9β1 MFI 
Finally, a two-sided Student’s paired t-test was used to individually assess the main effects 
of BAM, Time, and Preservative from the RM-ANOVA model on log Integrin α9β1 MFI. There 
was a non-significant difference in log Integrin α9β1 MFI between Citrate and EDTA at Time 0 
hours with Streck. All other BAM comparisons, controlling for Time and Preservative, 
demonstrated significant changes in log Integrin α9β1 MFI (Table 7). 
The two-sided Student’s paired t-test was also used to assess the effect of each Time point 
on log Integrin α9β1 MFI, controlling for BAM and Preservative. Non-significant differences in 
log Integrin α9β1 MFI between Time 0 hours and Time 24 hours were generally revealed, with the 
exception of Heparin with Streck and EDTA with No Preservative (Table 8). 
The two-sided Student’s paired t-test was again used to assess the effect of each 
Preservative type on log Integrin α9β1 MFI, controlling for BAM and Time. All differences in log 
Integrin α9β1 MFI between the Preservative types were found to be significant (Table 9). 
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3.4 Evaluation of the Effect of Preservative Types and Time Points on ANC, CD11b 
MFI, and Log Integrin α9β1 MFI 
3.4.1  RM-ANOVA Model of ANC Adjusted for Preservative and Time 
Effects 
The overall RM-ANOVA model of ANC, adjusted for the main effects of Preservative and 
Time (Figure 25) and including the interaction between Preservative and Time, revealed 
significant differences in log ANC for the main effect of Preservative type (p <0.0001). The 
interaction between Preservative and Time was also significant (p <0.0001). The model did not 
demonstrate significant differences in log ANC due to Time (p = 0.453) and there was a relatively 
small effect size for this main effect (partial-η2 = 0.020). Large effect sizes were noted for 
Preservative and the interaction term (partial-η2 = 0.780 and 0.348, respectively).  
The change in log ANC over time was explored for each Preservative type. The average 
change in log ANC declined over time with No Preservative (Figure 26) but increased modestly 
with Streck (Figure 27) and BCT (Figure 28). The non-transformed values of ANC were assessed 
for change over Time at each Preservative type and demonstrated the same trends (Appendix D). 
Paired sample testing was performed using Wilcoxon Signed-Rank test or Student’s Paired 
T-Test, based on normality testing as described previously, in order to determine the effect of each 
discrete covariate in the RM-ANOVA model on the change in Log ANC. The effect of Preservative 
type at each Time point was assessed and all differences in log ANC were found to be significant, 
apart from non-significant differences in log ANC between Streck and BCT at both time points 
(Table 10). 
The effect of Time at each Preservative was evaluated and revealed significant differences 
in log ANC between Time points for Streck and BCT; however, there was a non-significant 
difference in log ANC over time with No Preservative (Table 11). 
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3.4.2  RM-ANOVA Model of CD11b MFI Adjusted for Preservative and 
Time Effects 
The overall RM-ANOVA model of CD11b MFI, adjusted for the main effects of 
Preservative and Time (Figure 29) and including the interaction between Preservative and Time, 
displayed significant differences in log CD11b MFI for the main effects of Preservative type (p 
<0.0001) and Time (p <0.0001). The interaction between Preservative and Time was also 
significant (p <0.0001). Large effect sizes were observed for the main effects and the interaction 
term (partial-η2 = 0.580 – 0.930). 
The change in log CD11b MFI over time was explored for each Preservative type. The 
average change in log CD11b MFI increased over time with No Preservative (Figure 30), Streck 
(Figure 31) and BCT (Figure 32). The non-transformed values of CD11b MFI were assessed for 
change over Time at each Preservative type and demonstrated the same trends (Appendix E). Of 
note, CD11b MFI was markedly elevated with No Preservative as compared to Streck and BCT. 
Paired sample testing was performed in order to determine the effect of each discrete 
covariate in the RM-ANOVA model on the change in log CD11b MFI. The effect of Preservative 
type at each Time point was assessed and all differences in log CD11b MFI were found to be 
significant, apart from a non-significant difference in log CD11b MFI between Streck and BCT at 
Time 24 hours (Table 12). 
The effect of Time at each Preservative was evaluated and revealed significant differences 
in log CD11b MFI between Time points for No Preservative, Streck, and BCT (Table 13). 
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3.4.3  RM-ANOVA Model of Integrin α9β1 MFI Adjusted for Preservative 
and Time Effects 
The overall RM-ANOVA model of Integrin α9β1 MFI, adjusted for the main effects of 
Preservative and Time (Figure 33) and including the interaction between Preservative and Time, 
exhibited significant differences in log Integrin α9β1 MFI for the main effects of Preservative type 
(p <0.0001) and Time (p <0.0001). The interaction between Preservative and Time was also 
significant (p <0.0001). Large effect sizes were observed for the main effects and the interaction 
term (partial-η2 = 0.461 – 0.897). 
The variability in log Integrin α9β1 MFI over time was evaluated for each Preservative 
type. The average change in log Integrin α9β1 MFI increased over time with No Preservative 
(Figure 34) and declined modestly over time with Streck (Figure 35) and BCT (Figure 36). The 
non-transformed values of Integrin α9β1 MFI were assessed for change over Time at each 
Preservative type and showed the same trends (Appendix F). 
Paired sample testing was performed in order to determine the effect of each discrete 
covariate in the RM-ANOVA model on the change in log Integrin α9β1 MFI. The effect of 
Preservative type at each Time point was assessed and all differences in log Integrin α9β1 MFI 
were found to be significant, except for a non-significant difference in log Integrin α9β1 MFI 
between Streck and BCT at Time 0 hours (Table 14). 
The effect of Time at each Preservative was evaluated and displayed significant differences 
in log CD11b MFI between Time points for No Preservative, Streck, and BCT (Table 15). 
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4.0 Discussion 
Flow cytometry is an established method to identify cell types from whole blood or plasma 
samples, as well as for cell-surface biomarker specification. Despite this, there exists a lack of 
consensus in the literature regarding the optimal specimen acquisition and preparation 
methodology for rapid, real-time neutrophil analysis. Many existing protocols utilize density 
gradients and fixatives that can alter cell-surface biomarker expression and bias counts of target 
populations. CD11b is a commonly measured neutrophil cell-surface biomarker; however, no 
existing protocol fit our specific needs for a rapid clinical test. Furthermore, Integrin α9β1 is a 
much less frequently measured neutrophil cell-surface biomarker; therefore, it was difficult to find 
protocols in the literature describing an approach to analyzing this biomarker and no existing 
protocol was suitable for our needs. Consequently, we developed a rapid lyse/no-wash method for 
clinical flow cytometry identification and enumeration of neutrophils, as well as the neutrophil 
cell-surface biomarkers CD11b and Integrin α9β1. The first stage of protocol development entailed 
testing and selecting an appropriate blood acquisition venipuncture tube (BAM) while the second 
stage of protocol development assessed the effects of three preservative states on our outcomes: 
CD11b MFI, Integrin α9β1 MFI, and absolute neutrophil count. The initial intent for this protocol 
was to incorporate a preservative to reduce sample degradation expected to occur in real-world 
clinical situations where there are varied intervals of time between sample collection and sample 
processing. Neutrophils have a short life span in vivo, approximately 24 hours, so preserving 
neutrophil integrity prior to sample processing is important for a clinical test reliant on neutrophils.  
The BAM experiment did not reveal a clearly superior choice of venipuncture tube; no 
preservative type or BAM reliably demonstrated greater consistency over time. There were 
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statistically significant interactions between BAM, Time, and Preservative for the overall RM-
ANOVA model of ANC. Reduced RM-ANOVA model testing for ANC was subsequently 
performed for each specific BAM and it revealed that Citrate had fewer significant differences in 
ANC attributable to the main effects and interaction terms in the model as compared to Heparin or 
EDTA. Further matched-pairs analysis of each main effect demonstrated the least ANC variability 
over time in Citrate with Streck or Heparin with No Preservative. Raw ANC values demonstrated 
a decline over time in Citrate, which was expected to occur due to cell degradation. This decline 
was mitigated by addition of Streck preservative; however, there were wide 95% confidence 
intervals surrounding the point estimate of the mean ANC in both preservative arms. ANC in 
Heparin or EDTA increased over time regardless of preservative type, and this was particularly 
marked in EDTA with Streck preservative, but Streck greatly narrowed the 95% confidence 
intervals for both Heparin and EDTA. Overall, EDTA with Streck preservative demonstrated the 
most variability in ANC over time. Since ANC cannot objectively increase with time, even in the 
absence of preservative, this must be interpreted as artifact.  
These findings suggest that for ANC, Citrate with Streck preservative is the least variable 
specimen collection and preservation option. However, the user should note that ANC declines by 
7.31% over time in this configuration and the 95% confidence intervals are wide for the point 
estimate of ANC at each time point and overlap the 95% confidence intervals of Heparin with 
Streck at Time 0 hours (Appendix A). Despite statistical significance of the changes in ANC noted 
over time and between BAM and preservative types, no changes were clinically significant. Streck 
preservative is a proprietary solution that contains EDTA, among many other ingredients. EDTA 
is a calcium chelating agent used to prevent clotting and preserve cell morphology, but it is possible 
that the composition of Streck interacts with the EDTA present in venipuncture tube resulting in 
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untoward neutrophil membrane changes and non-specific antibody binding. It is difficult to fully 
evaluate this possible confounding factor without a thorough understanding of the composition of 
Streck preservative solution. 
The overall RM-ANOVA model of CD11b MFI adjusted for the main effects of BAM, 
Time, and Preservative demonstrated that all main effects, except for Time, contributed to 
significant changes in CD11b MFI. The interaction terms for each main effect were also found to 
be significant. Analysis of each main effect using the Wilcoxon Signed-Rank test did not reveal 
superiority of any one BAM. Citrate with no preservative had the least absolute change in raw 
CD11b MFI over time, followed by Heparin with Streck solution, but the 95% confidence intervals 
were much wider for the point estimate of CD11b MFI in Citrate without preservative as compared 
to Heparin with Streck. EDTA demonstrated the most CD11b MFI variability overall. CD11b MFI 
declined by only 12.12% in Heparin with Streck, which was the smallest change in CD11b MFI 
over time compared to Citrate or EDTA with Streck (Appendix B). CD11b MFI increased over 
time in each BAM when no preservative was added. Streck mitigated this increase likely by 
reducing non-specific binding that occurs over time as the sample degrades. Based on this data, 
Heparin with Streck demonstrated the least variability for CD11b MFI. 
The overall RM-ANOVA model of Integrin α9β1 MFI, adjusted for the main effects and 
interaction terms, demonstrated that all main effects, except for Time, were significant in the model 
and all interactions between the main effects were significant, apart from the interaction between 
BAM, Time, and Preservative. Paired sample testing of each main effect revealed non-significant 
differences in log Integrin α9β1 MFI over time for Citrate with and without Streck as well as in 
Heparin without Streck, all other differences over time being significant. However, assessment of 
the raw Integrin α9β1 MFI showed that the point estimates of the mean had wide 95% confidence 
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intervals for Citrate with Streck, Heparin without Streck, and EDTA with either preservative. 
Additionally, Integrin α9β1 MFI increased over time for all BAM and preservative combinations 
except Heparin. Streck did reduce the increase in Integrin α9β1 MFI over time, likely by preventing 
non-specific binding. Heparin with Streck was determined to be the best specimen collection and 
preservation option for Integrin α9β1 because Integrin α9β1 MFI in Heparin exhibited a 
biologically plausible decline over time, as well as the least variability around the point estimate 
for Integrin α9β1 MFI (Appendix C). 
Heparin was chosen as the BAM method for this protocol because it demonstrated the most 
biologically plausible trajectory over time for CD11b and Integrin α9β1, as well as the least 
variable point estimates for ANC, CD11b MFI, and Integrin α9β1 MFI - particularly with the 
addition of Streck. Due to changes over time in each outcome of interest, samples should be 
processed as close to collection time as possible, although predictable increases in ANC as well as 
decreases in CD11b MFI and Integrin α9β1 MFI can be accounted for when interpreting results of 
these tests as long as they are performed within a 24-hour window. In order to verify the results of 
the preservative effect seen in the BAM analyses, subsequent experiments were conducted to more 
thoroughly evaluate the effects of preservative type and time on ANC, CD11b MFI, and Integrin 
α9β1 MFI. Heparin was used as the venipuncture blood collection tube for the No Preservative 
and Streck arms of the study, a specialized Streck Blood Collection Tube was also assessed.  
The overall RM-ANOVA model for variability of ANC adjusted for Preservative and Time 
revealed that only the Preservative main effect and the interaction between Preservative and Time 
were significant in the model. Paired sample testing of each main effect showed that ANC changed 
significantly between No Preservative and the two preservative types, but there was a non-
significant change between Streck and BCT. Additionally, although there was a significant change 
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in ANC over time for Streck and BCT, the actual change in ANC over time was only 8.36% for 
Streck, 6.89% for BCT, and 6.30% for No Preservative (Appendix D, Table 1). Clinically, these 
changes were not significant. The main effects and interaction term were significant in both overall 
RM-ANOVA models for change in CD11b MFI and Integrin α9β1 MFI. Changes in CD11b MFI 
and Integrin α9β1 MFI with Streck and BCT followed similar trends over time, which differed 
from the trends noted in the No Preservative arm. The MFI of CD11b was markedly different with 
No Preservative as compared to Streck and BCT, this could relate to non-specific binding. No such 
discrepancies were seen in the BAM analyses, so it is less likely that CD11b expression is being 
suppressed by the preservatives. CD11b MFI increased modestly over time in Streck and BCT, 
while there was a large increase over time in No Preservative. Integrin α9β1 MFI did not 
demonstrate such wild fluctuations between preservative types. Integrin α9β1 MFI declined over 
time in both Streck and BCT but increased in No Preservative. Streck preservative solution and 
Streck BCT were selected as the most optimal preservative methods due to their minimal 
variability over time for CD11b and Integrin α9β1 MFI. Additionally, the clinically insignificant 
changes in ANC over time negated the statistically significant differences noted over time for 
Streck and BCT. 
Streck and BCT proved to be the least variable preservative methods for the outcomes of 
interest. Streck solution is added in a 1:1 ratio to whole blood sample following specimen 
collection, while BCT is a separate venipuncture tube. Heparin is a common anticoagulant in 
hospitals and heparinized venipuncture tubes are widely available, whereas it is less cost effective 
and feasible for a hospital to purchase a separate blood collection tube (such as the Streck BCT) 
for a single laboratory test. Given these real-world concerns, Streck preservative solution added to 
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heparin venipuncture tubes is the most reasonable method by which to perform the rapid lyse/no-
wash neutrophil flow cytometric assay in a clinical setting. 
We did make slight adjustments to the biomarker panel between the BAM and Preservative 
experiments to streamline the gating scheme, this did not alter our outcomes of interest (Appendix 
G). CD11b and Integrin α9β1 biomarkers remained the same, but we incorporated CD66b PE-Cy7 
as a confirmatory neutrophil biomarker and removed CD33 APC-vio770 and CD14 PE-Cy7. CD16 
was changed from PE-Cy5 to APC-Cy7 for compatibility with the new biomarker panel.  Another 
limitation of the study are the discrepancies between the BAM, particularly related to change in 
ANC over time. Although Heparin with Streck showed less point estimate variability than Citrate 
or EDTA for all three outcomes of interest, the changes over time assessed by paired samples 
testing were more often significant in Heparin and EDTA. This emphasizes the important 
difference between statistical and clinical significance. Clinically, the differences in ANC are not 
impressive and the numerical variability can be accounted for over time. Further evaluation of any 
potential biological interactions between the preservatives tested in this study and CD11b and 
Integrin α9β1 would be useful to determine if the depressed MFIs are real or due to chemical 
interactions with the preservatives. Alternatively, the increased MFIs noted in the No Preservative 
samples could relate to non-specific binding that is prevented by the preservatives. Unfortunately, 
the preservatives are proprietary commercial products and the company has declined to share the 
ingredient list with the author; therefore, formal analysis into potential biological interactions 
cannot be completed at this time.  
In the future, replication of these studies in healthy subjects would be useful to confirm the 
findings herein. Additionally, extension of these studies in diseased populations would be useful 
to confirm the effects of BAM, Preservative type, and Time on ANC, CD11b MFI, and Integrin 
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α9β1 MFI and evaluate their diagnostic and prognostic value during an infectious challenge. This 
study demonstrates that specimen collection, preservation, and time to sample processing can 
result in significant changes in cell count and cell-surface membrane biomarker fluorescence. The 
results of this study highlight the importance of testing and standardizing sampling procedures and 
protocols in flow cytometric assays in advance of clinical or research applications. 
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5.0 Figures 
The 95% confidence intervals displayed in all figures depicting RM-ANOVA analyses 
represent 95% confidence intervals for the estimated marginal means in the model, not the 95% 
confidence intervals for the actual sample means. 
 
Figure 1. Overall RM-ANOVA Model for ANC Adjusted for BAM, Time Points, and Preservative Types 
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Figure 2. RM-ANOVA Model for ANC Adjusted for BAM and Time Points, with No Preservative 
 
 
Figure 3. RM-ANOVA Model for ANC Adjusted for BAM and Time Points, with Streck Preservative 
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Figure 4. Variability of ANC in Citrate Adjusted for Preservative Types and Time Points 
 
 
 
Figure 5. Variability of ANC in Heparin Adjusted for Preservative Types and Time Points 
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Figure 6. Variability of ANC in EDTA Adjusted for Preservative Types and Time Points 
 
 
 
Figure 7. Variability in ANC Adjusted for BAM and Preservative Type at Time 0 Hours 
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Figure 8. Variability in ANC Adjusted for BAM and Preservative Type at Time 24 Hours 
 
 
 
Figure 9. Overall RM-ANOVA Model for CD11b MFI Adjusted for BAM, Time Points, and Preservative Types 
 
 36 
 
 
Figure 10. RM-ANOVA Model for CD11b MFI Adjusted for BAM and Time Points, with No Preservative 
 
 
 
Figure 11. RM-ANOVA Model for CD11b MFI Adjusted for BAM and Time Points, with Streck Preservative 
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Figure 12. Variability of CD11b in Citrate Adjusted for Preservative Types and Time Points 
 
 
Figure 13. Variability of CD11b MFI in Heparin Adjusted for Preservative Types and Time Points 
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Figure 14. Variability of CD11b MFI in EDTA Adjusted for Preservative Types and Time Points 
 
 
 
Figure 15. Variability in CD11b MFI Adjusted for BAM and Preservative Types, at Time 0 Hours 
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Figure 16. Variability in CD11b MFI Adjusted for BAM and Preservative Types, at Time 24 Hours 
 
 
 
Figure 17. Overall RM-ANOVA Model for Integrin α9β1 MFI Adjusted for BAM, Time Points, and 
Preservative Types 
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Figure 18. RM-ANOVA Model for Integrin α9β1 MFI Adjusted for BAM and Time Points, with No 
Preservative 
 
 
 
Figure 19. RM-ANOVA Model for Integrin α9β1 MFI Adjusted for BAM and Time Points, with Streck 
Preservative 
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Figure 20. Variability of Integrin α9β1 MFI in Citrate Adjusted for Preservative Types and Time Points 
 
 
 
Figure 21. Variability of Integrin α9β1 MFI in Heparin Adjusted for Preservative Types and Time Points 
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Figure 22. Variability of Integrin α9β1 MFI in EDTA Adjusted for Preservative Types and Time Points 
 
 
 
Figure 23. Variability in Integrin α9β1 MFI Adjusted for BAM and Preservative Type at Time 0 Hours 
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Figure 24. Variability in Integrin α9β1 MFI Adjusted for BAM and Preservative Type at Time 24 Hours 
 
 
Figure 25. RM-ANOVA Model of Variability of Absolute Neutrophil Count Adjusted for Preservative Types 
and Time Points 
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Figure 26. Variability of Absolute Neutrophil Count over Time, with No Preservative 
 
 
Figure 27. Variability of Absolute Neutrophil Count over Time, with Streck Preservative Solution 
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Figure 28. Variability of Absolute Neutrophil Count over Time, with Streck BCT 
 
 
Figure 29. RM-ANOVA Model of Variability of CD11b MFI Adjusted for Preservative Types and Time Points 
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Figure 30. Variability of CD11b MFI over Time, with No Preservative 
 
Figure 31. Variability of CD11b MFI over Time, with Streck Preservative Solution 
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Figure 32. Variability of CD11b MFI over Time, with Streck BCT 
 
 
 
Figure 33. RM-ANOVA Model of Variability of Log Integrin α9β1 MFI Adjusted for Preservative Types and 
Time Points 
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Figure 34. Variability of Log Integrin α9β1 MFI over Time, with No Preservative 
 
 
Figure 35. Variability of Log Integrin α9β1 MFI over Time, with Streck Preservative Solution 
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Figure 36. Variability of Log Integrin α9β1 MFI over Time, with Streck BCT  
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6.0 Tables 
Table 1. Student’s Paired T-Test Evaluating the Effect of Each BAM on ANC 
 
Table 2. Student’s Paired T-Test Evaluating the Effect of Individual Time Points on ANC 
 
Table 3. Student’s Paired T-Test Evaluating the Effect of Preservative Type on ANC 
 
Table 4. Wilcoxon Signed-Rank Test Evaluating the Effect of each BAM on Log CD11b MFI 
 
Table 5. Wilcoxon Signed-Rank Test Evaluating the Effect of Individual Time Points on Log CD11b MFI 
 
                   BAM                                  No Preservative            Streck Preservative         
Time 0 hours Time 24 hours Time 0 hours Time 24 hours 
Citrate vs Heparin p <0.0001 p <0.0001 p = 0.79 p<0.0001 
Citrate vs EDTA p <0.0001 p = 0.0002 p = 0.0008 p = 0.0001 
Heparin vs EDTA p = 0.006 p = 0.0006 p = 0.004 p = 0.051 
 
         Time                           Citrate               Heparin                      EDTA 
No  
Preservative 
Streck No  
Preservative 
Streck No  
Preservative 
Streck 
0 vs 24 hours p = 0.03 p = 0.47 p = 0.07 p <0.0001  p = 0.002 p <0.0001 
 
 Preservative                       Citrate               Heparin                      EDTA 
Time 0 
hours 
Time 24  
hours 
Time 0 
hours 
Time 24  
hours 
Time 0 
hours 
Time 24  
hours 
No Preservative 
vs Streck 
p = 0.03 
 
p = 0.43 p = 0.0001 p <0.0001 p = 0.06 p <0.0001 
 
                   BAM                                  No Preservative            Streck Preservative         
Time 0 hours Time 24 hours Time 0 hours Time 24 hours 
Citrate vs Heparin p = 0.008 p = 0.26 p = 0.008 p = 0.008 
Citrate vs EDTA p = 0.008 p = 0.14 p = 0.008 p = 0.008 
Heparin vs EDTA p = 0.008 p = 0.02 p = 0.14 p = 0.008 
 
         Time                           Citrate               Heparin                      EDTA 
No  
Preservative 
Streck No  
Preservative 
Streck No  
Preservative 
Streck 
0 vs 24 hours p = 0.31 p = 0.008 p = 0.008 p = 0.01  p = 0.01 p = 0.008 
 
 51 
Table 6. Wilcoxon Signed-Rank Test Evaluating the Effect of Preservative Type on Log CD11b MFI 
 
Table 7. Student’s Paired T-Test Evaluating the Effect of each BAM on Log Integrin α9β1 MFI 
 
Table 8. Student’s Paired T-Test Evaluating the Effect of Individual Time Points on Log Integrin α9β1 MFI 
 
Table 9. Student’s Paired T-Test Evaluating the Effect of Preservative Type on Log Integrin α9β1 MFI 
 
Table 10. Student’s Paired T-Test Evaluating the Effect of Preservative Type on Log ANC 
 
Table 11. Student’s Paired T-Test and Wilcoxon Signed-Rank Test* Evaluating the Effect of Time on Log ANC 
 
 
 Preservative                       Citrate               Heparin                      EDTA 
Time 0 
hours 
Time 24  
hours 
Time 0 
hours 
Time 24  
hours 
Time 0 
hours 
Time 24  
hours 
No Preservative 
vs Streck 
p = 0.09 
 
p = 0.008 p = 0.051 p <0.008 p = 0.008 p = 0.008 
 
                   BAM                                  No Preservative            Streck Preservative         
Time 0 hours Time 24 hours Time 0 hours Time 24 hours 
Citrate vs Heparin p <0.0001 p = 0.009 p <0.0001 p <0.0001 
Citrate vs EDTA p = 0.042 p = 0.003 p = 0.487 p = 0.008 
Heparin vs EDTA p <0.0001 p = 0.019 p = 0.0006 p <0.0001 
 
         Time                           Citrate               Heparin                      EDTA 
No  
Preservative 
Streck No  
Preservative 
Streck No  
Preservative 
Streck 
0 vs 24 hours p = 0.089 p = 0.086 p = 0.493 p <0.0001  p = 0.005 p = 0.651 
 
 Preservative                       Citrate               Heparin                      EDTA 
Time 0 
hours 
Time 24  
hours 
Time 0 
hours 
Time 24  
hours 
Time 0 
hours 
Time 24  
hours 
No Preservative 
vs Streck 
p = 0.0002 
 
p <0.0001 p <0.0001 p <0.0001 p = 0.002 p <0.0001 
 
 Time 0 Hours Time 24 Hours 
No Preservative vs Streck p <0.0001 p <0.0001 
No Preservative vs BCT p <0.0001 p <0.0001 
Streck vs BCT p = 0.492 p = 0.387 
 
 No Preservative Streck* BCT* 
Time 0 vs Time 24 
hours 
p = 0.055 p = 0.0003 p = 0.020 
*Wilcoxon Signed-Rank Test used for Streck and BCT analyses 
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Table 12. Wilcoxon Signed-Rank Test Evaluating the Effect of Preservative Type on Log CD11b MFI 
 
Table 13. Wilcoxon Signed-Rank Test Evaluating the Effect of Time on Log CD11b MFI 
 
Table 14. Student’s Paired T-Test Evaluating the Effect of Preservative Type on Log Integrin α9β1 MFI 
 
Table 15. Student’s Paired T-Test and Wilcoxon Signed-Rank Test* the Effect of Time on Log Integrin α9β1 
MFI 
 
 Time 0 Hours Time 24 Hours 
No Preservative vs Streck p <0.0001 p <0.0001 
No Preservative vs BCT p <0.0001 p <0.0001 
Streck vs BCT p = 0.013 p = 0.720 
 
 No Preservative Streck BCT 
Time 0 vs Time 24 
hours 
p <0.0001 p = 0.007 p <0.0001 
 
 Time 0 Hours Time 24 Hours 
No Preservative vs Streck p <0.0001 p <0.0001 
No Preservative vs BCT p <0.0001 p <0.0001 
Streck vs BCT p = 0.538 p <0.0001 
 
 No Preservative Streck* BCT 
Time 0 vs Time 24 
hours 
p = 0.006 p <0.0001 p = 0.002 
**Wilcoxon Signed-Rank Test used for Streck analysis 
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Appendix A Change in ANC over time for each BAM 
 
Appendix A, Figure 1. Absolute Neutrophil Count in Citrate from Time 0 Hours to Time 24 Hours, with No 
Preservative 
 
 
Appendix A, Figure 2. Absolute Neutrophil Count in Citrate from Time 0 Hours to Time 24 Hours, with Streck 
Preservative 
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Appendix A, Figure 3. Absolute Neutrophil Count in Heparin from Time 0 Hours to Time 24 Hours, with No 
Preservative 
 
 
 
 
 
 
 
 
 
Appendix A, Figure 4. Absolute Neutrophil Count in Heparin from Time 0 Hours to Time 24 Hours, with Streck 
Preservative 
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Appendix A, Figure 5. Absolute Neutrophil Count in EDTA from Time 0 Hours to Time 24 Hours, with No 
Preservative 
 
 
Appendix A, Figure 6. Absolute Neutrophil Count in EDTA from Time 0 Hours to Time 24 Hours, with Streck 
Preservative 
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Appendix A, Table 1. Average Change in ANC over Time for each BAM 
 
Appendix A, Table 2. ANC Coefficient of Variation for each BAM at each Preservative Type 
and Time Point 
 
BAM Time 0 Time 24 Total Change Percent Change 
Citrate No 
Preservative 
2447 2132.33 -314.67 12.86% 
Streck 2126.22 1970.89 -155.33 7.31% 
Heparin  No 
Preservative 
784.5171 912.7462 +128.23 16.34% 
Streck 2079.1851 3168.4546 +1089.27 52.39% 
EDTA No 
Preservative 
1071.0542 1309.7691 +238.71 22.29% 
Streck 1381.8499 3076.5728 +1694.72 122.64% 
 
BAM Time 0 Hours Time 24 Hours 
Citrate No Preservative 5.91% 8.77% 
Streck  10.23% 12.89% 
Heparin No Preservative 11.51% 7.50% 
Streck  7.14% 2.74% 
EDTA No Preservative 5.06% 4.12% 
Streck  28.87% 2.91% 
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Appendix B Change in CD11b MFI over time for each BAM 
 
Appendix B, Figure 1. CD11b MFI in Citrate from Time 0 Hours to Time 24 Hours, with No Preservative 
 
 
Appendix B, Figure 2. CD11b MFI in Citrate from Time 0 Hours to Time 24 Hours, with Streck Preservative 
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Appendix B, Figure 3. CD11b MFI in Heparin from Time 0 Hours to Time 24 Hours, with No Preservative 
 
 
Appendix B, Figure 4. CD11b MFI in Heparin from Time 0 Hours to Time 24 Hours, with Streck Preservative 
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Appendix B, Figure 5. CD11b MFI in EDTA from Time 0 Hours to Time 24 Hours, with No Preservative 
 
 
Appendix B, Figure 6. CD11b MFI in EDTA from Time 0 Hours to Time 24 Hours, with Streck Preservative 
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Appendix B, Table 1. Average Change in CD11b MFI over Time for each BAM 
 
Appendix B, Table 2. CD11b MFI Coefficient of Variation for each BAM at each 
Preservative Type and Time Point 
 
BAM Time 0 Time 24 Total Change Percent Change 
Citrate  No 
Preservative 
20789.33 21560.33 +771.00 3.71% 
Streck 19136.44 12748.56 -6387.88 33.38% 
Heparin  No 
Preservative 
10953.3656 19598.3226 +8644.96 78.93% 
Streck 9725.1777 8546.0456 -1179.13 12.12% 
EDTA  No 
Preservative 
14025.9233 29791.3990 +15765.48 112.40% 
Streck 11191.9934 7277.3778 -3914.62 34.98% 
 
BAM Time 0 Hours Time 24 Hours 
Citrate No Preservative 5.44% 7.18% 
Streck  2.32% 1.99% 
Heparin No Preservative 3.35% 6.55% 
Streck  2.71% 1.82% 
EDTA No Preservative 2.24% 17.59% 
Streck  6.23% 3.35% 
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Appendix C Change in Integrin α9β1 MFI over Time for each BAM 
 
Appendix C, Figure 1. Integrin a9b1 MFI in Citrate from Time 0 Hours to Time 24 Hours, with No Preservative 
 
 
Appendix C, Figure 2. Integrin a9b1 MFI in Citrate from Time 0 Hours to Time 24 Hours, with Streck 
Preservative 
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Appendix C, Figure 3. Integrin a9b1 MFI in Heparin from Time 0 Hours to Time 24 Hours, with No 
Preservative 
 
 
Appendix C, Figure 4. Integrin a9b1 MFI in Heparin from Time 0 Hours to Time 24 Hours, with Streck 
Preservative 
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Appendix C, Figure 5. Integrin a9b1 MFI in EDTA from Time 0 Hours to Time 24 Hours, with No Preservative 
 
 
Appendix C, Figure 6. Integrin a9b1 MFI in EDTA from Time 0 Hours to Time 24 Hours, with Streck 
Preservative 
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Appendix C, Table 1. Average Change in Integrin α9β1 MFI over Time for each BAM 
 
Appendix C, Table 2. Integrin α9β1 MFI Coefficient of Variation for each BAM at each 
Preservative Type and Time Point 
 
BAM Time 0 Time 24 Total Change Percent 
Change 
Citrate  No 
Preservative 
23328.00 25325.39 +1997.39 8.56% 
Streck 17309.78 17959.44 +649.66 3.75% 
Heparin  No 
Preservative 
33726.6224 32978.3854 -748.237 2.22% 
Streck 28957.8466 21830.2912 -7127.56 24.61% 
EDTA  No 
Preservative 
26247.0866 35134.3676 +8887.28 33.86% 
Streck 16753.9535 16782.5275 +28.57 0.17% 
 
BAM Time 0 Hours Time 24 Hours 
Citrate No Preservative 4.48% 7.92% 
Streck  3.52% 3.37% 
Heparin No Preservative 2.98% 4.57% 
Streck  2.72% 2.73% 
EDTA No Preservative 3.06% 1.59% 
Streck  29.02% 1.62% 
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Appendix D Variability in Absolute Neutrophil Count over Time at each Preservative Type 
 
Appendix D, Figure 1. Variability of Absolute Neutrophil Count over Time, with No Preservative 
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Appendix D, Figure 2. Variability of Absolute Neutrophil Count over Time, with Streck Preservative Solution 
 
 
Appendix D, Figure 3. Variability of Absolute Neutrophil Count over Time, with Streck Blood Collection Tube 
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Appendix D, Table 1. Average Change in ANC over Time for each Preservative Type 
 
Preservative Time 0  Time 24  Total Change Percent Change 
No Preservative 2435.382 2282.038 - 153.344 6.30% 
Streck 2851.431 3089.891 + 238.460 8.36% 
BCT 2827.927 3022.725 + 194.798 6.89% 
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Appendix E Variability in CD11b MFI over Time at each Preservative Type 
 
Appendix E, Figure 1. Variability of CD11b MFI over Time, with No Preservative 
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Appendix E, Figure 2. Variability of CD11b MFI over Time, with Streck Preservative Solution 
 
 
Appendix E, Figure 3. Variability of CD11b MFI over Time, with Streck Blood Collection Tube 
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Appendix E, Table 1. Average Change in CD11b MFI over Time for each Preservative Type 
 
Preservative Time 0  Time 24  Total Change Percent Change 
No Preservative 32269.100 78993.940 + 46724.840 144.80% 
Streck 5717.239 6388.348 + 671.109 11.74% 
BCT 4256.392 5916.869 + 1660.477 39.01% 
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Appendix F Variability in Integrin α9β1 MFI over Time at each Preservative Type 
 
Appendix F, Figure 1. Variability of Integrin a9b1 MFI over Time, with No Preservative 
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Appendix F, Figure 2. Variability of Integrin a9b1 MFI over Time, with Streck Preservative Solution 
 
 
Appendix F, Figure 3. Variability of Integrin a9b1 MFI over Time, with Streck Blood Collection Tube 
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Appendix F, Table 1. Average Change in Integrin α9β1 MFI over Time for each Preservative 
Type 
 
Preservative Time 0  Time 24  Total Change Percent Change 
No Preservative 13787.530 14790.340 + 1002.810 7.27% 
Streck 11069.430 9077.850 - 1991.580 17.99% 
BCT 10956.140 10278.630 - 677.510 6.18% 
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Appendix G . Gating Schemes 
 
Appendix G, Figure 1. Representative Gating Scheme for BAM Analyses  
Gated through B (not beads): D – Neutrophils, E – Monocytes, C – Lymphocytes, F – Eosinophils  
 
 
Appendix G, Figure 2. Representative Gating Scheme for Preservative Analyses  
Gated through B (not beads) and D (all cells): C – Neutrophils, O – Monocytes, L – Lymphocytes   
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